PH12020551313B1 - Ophthalmic composition comprising diquafosol and cationic polymer - Google Patents

Ophthalmic composition comprising diquafosol and cationic polymer

Info

Publication number
PH12020551313B1
PH12020551313B1 PH1/2020/551313A PH12020551313A PH12020551313B1 PH 12020551313 B1 PH12020551313 B1 PH 12020551313B1 PH 12020551313 A PH12020551313 A PH 12020551313A PH 12020551313 B1 PH12020551313 B1 PH 12020551313B1
Authority
PH
Philippines
Prior art keywords
cationic
copolymer
hydrolyzed
diquafosol
ophthalmic composition
Prior art date
Application number
PH1/2020/551313A
Other languages
English (en)
Other versions
PH12020551313A1 (en
Inventor
Hiroyuki Asada
Kenichi Endo
Asuka Kamimura
Yusuke Momokawa
Kenji Morishima
Kyohei Takahashi
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PH12020551313A1 publication Critical patent/PH12020551313A1/en
Publication of PH12020551313B1 publication Critical patent/PH12020551313B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PH1/2020/551313A 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer PH12020551313B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035578 2018-02-28
PCT/JP2019/007542 WO2019168023A1 (ja) 2018-02-28 2019-02-27 ジクアホソルおよびカチオン性ポリマーを含有する眼科用組成物

Publications (2)

Publication Number Publication Date
PH12020551313A1 PH12020551313A1 (en) 2021-09-06
PH12020551313B1 true PH12020551313B1 (en) 2024-02-28

Family

ID=67806273

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2020/551313A PH12020551313B1 (en) 2018-02-28 2019-02-27 Ophthalmic composition comprising diquafosol and cationic polymer

Country Status (14)

Country Link
US (1) US20210000844A1 (enExample)
EP (1) EP3760207A4 (enExample)
JP (4) JP6716800B2 (enExample)
KR (3) KR102472773B1 (enExample)
CN (2) CN111757742B (enExample)
BR (1) BR112020017661A2 (enExample)
CA (1) CA3091700A1 (enExample)
EA (1) EA202092030A1 (enExample)
MX (2) MX2020008925A (enExample)
PH (1) PH12020551313B1 (enExample)
SG (1) SG11202007977RA (enExample)
TW (3) TWI898399B (enExample)
UA (1) UA129517C2 (enExample)
WO (1) WO2019168023A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210000844A1 (en) * 2018-02-28 2021-01-07 Santen Pharmaceutical Co., Ltd. Ophthalmic composition comprising diquafosol and cationic polymer
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
CN114286670B (zh) * 2019-08-27 2024-01-16 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
CN113712910A (zh) * 2021-08-05 2021-11-30 广州市桐晖药业有限公司 一种滴眼液及其制备方法
KR102794468B1 (ko) 2022-04-04 2025-04-14 서울대학교산학협력단 감미 억제용 조성물 및 식품의 감미 억제 방법
KR20250038935A (ko) * 2023-09-13 2025-03-20 루다큐어 주식회사 8-옥소-2'-데옥시구아노신 또는 이의 약학적으로 허용가능한 염을 포함하는 수용액 형태의 점안제
KR20250160050A (ko) 2024-05-03 2025-11-11 삼천당제약주식회사 물리화학적 특성이 개선된 안구건조증 예방 또는 치료용 약학 조성물
CN119970633A (zh) * 2025-03-26 2025-05-13 苏州乐珠制药有限公司 一种地夸磷索钠滴眼液及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01294620A (ja) 1988-05-19 1989-11-28 Kissei Pharmaceut Co Ltd 水溶液製剤およびその製造方法
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
JP3155689B2 (ja) * 1995-08-10 2001-04-16 昭和薬品化工株式会社 消炎点眼剤
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
DK1012154T3 (da) 1997-07-25 2004-07-26 Inspire Pharmaceuticals Inc Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
JP2001294620A (ja) 2000-04-11 2001-10-23 Showa Denko Kk プラスチックレンズ材料、該材料の製造方法、プラスチックレンズ用組成物、該組成物を硬化してなるプラスチックレンズ、及び該プラスチックレンズの製造方法
KR100832821B1 (ko) * 2000-05-30 2008-05-28 산텐 세이야꾸 가부시키가이샤 각막 상피 신장 촉진제
KR101484499B1 (ko) * 2005-02-14 2015-01-20 존슨 앤드 존슨 비젼 케어, 인코포레이티드 안과용 렌즈의 제조방법, 안과용 장치 및 콘택트 렌즈
JP4515960B2 (ja) 2005-05-19 2010-08-04 株式会社資生堂 整髪料洗浄剤及びその使用方法
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
US20090118243A1 (en) * 2007-10-12 2009-05-07 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
WO2009110009A2 (en) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd., Opthalmic composition
CN103282039A (zh) * 2010-12-28 2013-09-04 参天制药株式会社 含有地夸磷索的滴眼液及其制备方法、抑制不溶性析出物产生的方法
SG11201405799TA (en) * 2012-03-26 2014-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
CA2947065C (en) * 2014-05-07 2022-04-19 Croma-Pharma Gesellschaft M.B.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
JPWO2015190483A1 (ja) * 2014-06-10 2017-04-20 ロート製薬株式会社 眼科用水性組成物
TWI709405B (zh) * 2014-12-25 2020-11-11 日商參天製藥股份有限公司 水性點眼液及其應用
KR101587385B1 (ko) 2015-07-29 2016-01-21 국제약품공업주식회사 사이클로스포린 함유 무자극성의 안약조성물 및 편리한 제조방법
JP2017043607A (ja) * 2015-08-24 2017-03-02 参天製薬株式会社 眼科用フィルム製剤
PL3266446T3 (pl) * 2016-07-07 2019-05-31 Salvat Lab Sa Kompozycja oftalmiczna zawierająca olej rycynowy i trójgliceryd o średniej długości łańcucha
CN106772747B (zh) * 2016-12-26 2022-10-18 深圳市光科全息技术有限公司 一种光学膜及其制作方法
MX2018014935A (es) * 2017-04-25 2019-04-09 Wakamotot Pharmaceutical Co Ltd Lagrima artificial de gelificacion termo-responsiva.
JP6582029B2 (ja) * 2017-10-03 2019-09-25 株式会社メニコン 眼科用組成液及びその使用方法
US20210000844A1 (en) 2018-02-28 2021-01-07 Santen Pharmaceutical Co., Ltd. Ophthalmic composition comprising diquafosol and cationic polymer
CN108853016A (zh) * 2018-09-26 2018-11-23 广州大光制药有限公司 一种地夸磷索钠滴眼液及其制备方法
JP7526718B2 (ja) * 2019-02-27 2024-08-01 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
CN114286670B (zh) * 2019-08-27 2024-01-16 参天制药株式会社 含有地夸磷索或其盐、及聚乙烯吡咯烷酮的水性眼科用组合物

Also Published As

Publication number Publication date
KR20250053220A (ko) 2025-04-21
TWI898399B (zh) 2025-09-21
EP3760207A1 (en) 2021-01-06
WO2019168023A1 (ja) 2019-09-06
KR102472773B1 (ko) 2022-11-30
JP7472202B2 (ja) 2024-04-22
BR112020017661A2 (pt) 2020-12-22
JP2022136152A (ja) 2022-09-15
MX2020008925A (es) 2020-10-01
CN117137866A (zh) 2023-12-01
JP2024045506A (ja) 2024-04-02
JP2020138980A (ja) 2020-09-03
US20210000844A1 (en) 2021-01-07
CN111757742B (zh) 2023-09-26
TW202000212A (zh) 2020-01-01
JP7297718B2 (ja) 2023-06-26
SG11202007977RA (en) 2020-09-29
TWI781296B (zh) 2022-10-21
TW202306572A (zh) 2023-02-16
JPWO2019168023A1 (ja) 2020-05-28
CA3091700A1 (en) 2019-09-06
UA129517C2 (uk) 2025-05-21
CN111757742A (zh) 2020-10-09
EP3760207A4 (en) 2023-10-04
TW202423451A (zh) 2024-06-16
KR20220163519A (ko) 2022-12-09
KR102796051B1 (ko) 2025-04-14
EA202092030A1 (ru) 2020-11-16
MX2022014791A (es) 2023-01-16
JP6716800B2 (ja) 2020-07-01
KR20200127002A (ko) 2020-11-09
PH12020551313A1 (en) 2021-09-06
TWI833406B (zh) 2024-02-21

Similar Documents

Publication Publication Date Title
PH12020551313B1 (en) Ophthalmic composition comprising diquafosol and cationic polymer
EP4445954A3 (en) Cellular models of and therapies for ocular diseases
WO2017143239A8 (en) Systems and methods for augmented reality representations of networks
EP4003225A4 (en) BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
MX2020012200A (es) Bata.
BR0205199A (pt) Polìmeros de radical livre catiÈnicos ou anfóteros, utilização dos mesmos, composição cosmética, e, processos para o tratamento de materiais de queratina e para a realização de penteados
MY199333A (en) Olefin-olefinic alcohol copolymer, and preparation method therefor
WO2004004757A8 (en) Treatment for eye disorder
GB2610445B (en) Eyecup, headband, and eye mask for sleeping
BR112018072343A2 (pt) método de determinação de um filtro para uma lente oftálmica em função de uma grandeza representativa de uma sensibilidade dinâmica do olho de um portador a uma variação de um fluxo luminoso
MX2019013363A (es) Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
EP3863576A4 (en) PHOTOACTIVATION SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING TREATMENTS
PH12019501869A1 (en) Virtual reality head-mounted apparatus
PH12019500934A1 (en) Opthalmic solution comprising epinastine
MX2022011077A (es) Variantes de transglutaminasa.
EP3741241A3 (en) Improvement to facemasks
ATE482003T1 (de) Kosmetische zubereitung mit wachskomponente, filmbildner und gelkomponente
NO20025251L (no) Materiale for belegning av pölser og hard ost
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
PH12017501996A1 (en) Wig base and wig
TH2001004832A (th) องค์ประกอบสำหรับหยอดตาที่ประกอบรวมด้วยไดควาโฟซอลและพอลิเมอร์ประจุบวก
PH12019502335A1 (en) Thermo-responsive gelling artificial lacrima
KR102588306B9 (ko) 환자의 두개골의 크기와 형태, 촬영 방향 등에 따라 생기는 다양성을 최소화할 수 있는 인공지능 기반 장치 및 방법
ATE548006T1 (de) Hörgerät und verfahren zur seiner herstellung
EP4192903A4 (en) SULFOPOLYESTERS COMPRISING 1,4-CYCLOHEXANEDIMETHANOL